Trial Profile
Evaluating the Efficacy and Safety of Extended Release Hydromorphone (Exalgo) in Patients With Neuropathic Pain: An Open Label Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Jun 2012
Price :
$35
*
At a glance
- Drugs Hydromorphone (Primary)
- Indications Neuropathic pain
- Focus Therapeutic Use
- 19 Jun 2012 Actual end date (Sep 2011) added as reported by ClinicalTrials.gov.
- 19 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 29 Sep 2010 New trial record